Welcome to the official Investor Relations profile of NeOnc Technologies (NASDAQ: NTHI).
Joined October 2025
- Tweets84
- Following1
- Followers5
- Likes2
Today's PR reinforces that a single number doesn't define clinical development; it's built through evidence. NEO100 met its primary endpoint by more than doubling the pre-specified benchmark (48.9% vs. 20%). The study reported a median overall survival of 26.1 months. $NTHI
$NTHI Leadership Update: NeOnc Technologies Holdings Inc. has appointed strategy and finance executive Nasim Shomali to its Board of Directors.
#NeOnc #NTHI #Biotechnology #Leadership #CorporateStrategy #Oncology #CNSCancer #ClinicalDevelopment
investors.neonc.com/news-rel…
Watch: NeOnc Technologies (NASDAQ: NTHI) has received Investigational New Drug (IND) approval from health regulators in Abu Dhabi for its lead drug candidate, NEO100.
youtube.com/watch?v=SOD20zoi…
#NeOnc #NTHI #NEO212 #FDA #Biotech #DrugDevelopment
📣 FDA Update: $NTHI NeOnc Receives Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
#NeOnc #NTHI #NEO212 #FDA #Biotech #DrugDevelopment
investors.neonc.com/news-rel…
What we’re building at NeOnc Technologies is focused on one of the hardest challenges in neuro-oncology: delivering therapies to the brain.
For patients facing devastating CNS cancers, the “why” is clear: better delivery and continued progress toward addressing urgent unmet need.
Watch: New to the Street TV Presents - NeOnc Receives Abu Dhabi IND Approval for Brain Cancer Drug NEO100
#NeOnc #NTHI #BrainCancer #ClinicalTrials #Biotechnology #Innovation
youtube.com/watch?v=SOD20zoi…
A quote from Amir Heshmatpour, CEO, Executive Chairman, and President of NeOnc Technologies, on the recent UAE approval for NEO100. #NeOnc #NTHI #BrainCancer #ClinicalTrials #Biotechnology #Innovation
$NTHI is pleased to announce that NEO100 has received Investigational New Drug (IND) authorization from the Department of Health, Abu Dhabi.
Read more: investors.neonc.com/news-rel…
A quote from Amir Heshmatpour, CEO, Executive Chairman, and President of NeOnc Technologies, on the recent UAE IND approval for NEO212.
#NeOnc #NTHI #BrainCancer #Biotech #ClinicalTrials #UAE #AbuDhabi $NTHI
$NTHI NeOnc Technologies is proud to announce that we’ve secured UAE IND approval for NEO212 following successful Phase 1 completion, advancing toward global Phase 2 development.
Read more about this exciting news here: investors.neonc.com/news-rel…
ICYMI: In a recent interview with Lou Basenese, NeOnc Technologies CEO Amir Heshmatpour discussed the company’s innovative intranasal drug delivery platform designed to bypass the blood-brain barrier and deliver therapies directly to the brain.
youtube.com/watch?v=pUksENi0…
Watch: $NTHI reported first-quarter 2026 financial results while highlighting progress across its clinical-stage programs targeting central nervous system cancers.
youtube.com/watch?v=VbMt9znH…
Institutional awareness of $NTHI continued to grow in May with 2 analyst firms initiating coverage:
🔹 Maxim Group: Buy | $20 Price Target
🔹 BTIG: Buy | $15 Price Target
Learn more about our latest announcements and Investor Relations updates at investors.neonc.com.
$NTHI May demonstrated continued progress across multiple areas of the business, including clinical development, regulatory preparation, financial management, & growing awareness.
Explore latest company news & insights in our IR section: investors.neonc.com/?_gl=1*h…
ICYMI: NeOnc Reports Tumor Remission Data & Advances Brain Cancer Treatment Platform $NTHI
youtube.com/watch?v=EkDQ8ONv…
We appreciate seeing thoughtful discussion on Reddit and across the broader biotech investor community surrounding NeOnc Technologies and the Company’s NEO100 clinical program.
$NTHI #Biotech #Glioblastoma #BrainCancer
reddit.com/r/GrowthStocks/co…
NeOnc Technologies Holdings, Inc. ($NTHI) received new analyst coverage from Maxim Group, which initiated coverage with a Buy rating and a $20 price target.
Read more here: maxim.bluematrix.com/sellsid…
NeOnc Technologies (Nasdaq: $NTHI) is proud to share Q1 2026 financial results and provide a business update highlighting continued progress across both of our clinical-stage CNS oncology programs.
Read the full announcement here: investors.neonc.com/news-rel…